تحميل
NASDAQHealthcareMedical - Devices
أحدث البيانات المتاحة
4.06 US$
−0.07 US$ · -1.69%
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
الإغلاق السابق
4.06 US$
−0.07 US$ · -1.69%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
نطاق اليوم
السعر الحالي 4.06 US$
نطاق 52 أسبوعًا
السعر الحالي 4.06 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
77
أقل من القيمة
المشاعر
54
مختلط
المخاطر
62
مخاطر مرتفعة
الزخم
35
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
نطاق اليوم
السعر الحالي 4.06 US$
نطاق 52 أسبوعًا
السعر الحالي 4.06 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
11.00 US$
ارتفاع محتمل بنسبة 170.94%عينة محدودة من 4 تقييمات
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI5.65 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM4.71 مليون0.01%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF2.7 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO1.71 مليون0.01%13.92 مليار USD0.24%356.78 US$+0.94%
Vanguard Russell 2000 ETFVTWO1.36 مليون0.01%18 مليار USD0.06%112.66 US$+0.50%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS1.22 مليون0.31%398.85 مليون USD0.60%107.24 US$+1.40%
iShares Micro-Cap ETFIWC573.54 ألف0.04%1.32 مليار USD0.60%183 US$+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM260 ألف0.22%116.88 مليون USD0.73%15.9402 US$+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
